Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019023786) COMBINATION THERAPIES FOR INHIBITION OF TTK PROTEIN KINASE
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/023786 International Application No.: PCT/CA2017/050920
Publication Date: 07.02.2019 International Filing Date: 01.08.2017
IPC:
A61K 31/519 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/00 (2006.01) ,A61P 37/02 (2006.01) ,C07D 487/04 (2006.01) ,C07K 16/28 (2006.01) ,C07K 16/30 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
02
Immunomodulators
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
487
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
Applicants:
UNIVERSITY HEALTH NETWORK [CA/CA]; 190 Elizabeth Street R. Fraser Elliott Building - Room 1S-417 Toronto, Ontario M5G 2C4, CA
Inventors:
BRAY, Mark Robert; CA
MASON, Jacqueline M.; CA
MAK, Tak W.; CA
FLETCHER, Graham; CA
Agent:
BAKER, James D.; CA
BOWN, Christopher D.; CA
NEWTON, Trevor; CA
LEDWELL, M. Kent; CA
ROY, Matthew; CA
SCHROEDER, Hans; CA
SPRIGINGS, Mark; CA
WILKIE, Jennifer; CA
Priority Data:
Title (EN) COMBINATION THERAPIES FOR INHIBITION OF TTK PROTEIN KINASE
(FR) THÉRAPIES COMBINÉES POUR L'INHIBITION DE LA PROTÉINE KINASE TTK
Abstract:
(EN) Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.
(FR) La présente invention concerne des procédés de traitement du cancer en utilisant une quantité efficace d'un composé représenté par la formule ou d'un sel pharmaceutiquement acceptable de celui-ci et une quantité efficace d'un inhibiteur de point de contrôle immunitaire. L'invention concerne également des compositions comprenant le même composé représenté par la formule présentée ci-dessus ou un sel pharmaceutiquement acceptable de celui-ci et un inhibiteur de point de contrôle immunitaire.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)